The Burgess Group Selects Concert Genetics to Power Genetic Test Claims Payment Automation
News provided by
Share this article
Share this article
ALEXANDRIA, Va. and NASHVILLE, Tenn., Dec. 15, 2020 /PRNewswire/ The Burgess Group ( Burgess ), a HealthEdge company, an innovative payment integrity software company focused on improving healthcare payment operations through technology, has selected Concert Genetics to deliver genetic testing claim edits within the Burgess Source® claims payment automation and business intelligence platform.
The solution integrates Concert s real-time claim editing capabilities, powered by patented machine learning capabilities, into Burgess Source, which enables complete claims payment automation through up-to-date regulatory content, claims pricing and editing, and real-time analytics tools.
Concert Genetics and Trapelo Health Partner to Advance Molecular Oncology Decision Support
Partnership Seeks to Lower Barriers to Evidence-Based Molecular Oncology Care by Extending Trapelo s Decision Support Solutions Through Concert s Network of Laboratories and Health Plans
News provided by
Share this article
Share this article
BURLINGTON, Mass. and NASHVILLE, Tenn., Dec. 10, 2020 /PRNewswire/ Concert Genetics and Trapelo Health announced today that they have partnered to provide a streamlined, integrated solution that will expand access to evidence-based, genomic-informed oncology decision support.
(PRNewsfoto/Trapelo Health)
The partnership is built on a shared mission to improve connectivity, transparency, and alignment among the healthcare stakeholders that support the delivery of oncology care. It combines the unique strengths of the two organizations: Concert s genetic testing data and digital infrastructure and Trapelo s expertise in molecular oncology decision s